Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Management of Treatment-Resistant Depression: Challenges and Strategies</p>
Daphne Voineskos, Zafiris J. Daskalakis, Daniel M. Blumberger
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 221-234
Open Access | Times Cited: 313

Showing 26-50 of 313 citing articles:

Electroconvulsive therapy in treatment resistant depression
Subha Subramanian, Ruthzaine Lopez, Charles F. Zorumski, et al.
Journal of the Neurological Sciences (2021) Vol. 434, pp. 120095-120095
Closed Access | Times Cited: 44
Impact of the COVID-19 pandemic on remote mental healthcare and prescribing in psychiatry: an electronic health record study
Rashmi Patel, Jessica Irving, Aimee Brinn, et al.
BMJ Open (2021) Vol. 11, Iss. 3, pp. e046365-e046365
Open Access | Times Cited: 43
Repetitive transcranial magnetic stimulation (rTMS) in bipolar disorder: A systematic review
Gerasimos Konstantinou, Jeanette Hui, Abigail Ortiz, et al.
Bipolar Disorders (2021) Vol. 24, Iss. 1, pp. 10-26
Closed Access | Times Cited: 42
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
Naghmeh Nikkheslat
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100383-100383
Open Access | Times Cited: 42
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, et al.
Addiction Neuroscience (2022) Vol. 3, pp. 100025-100025
Open Access | Times Cited: 36
The Problem of Malnutrition Associated with Major Depressive Disorder from a Sex-Gender Perspective
Cielo García‐Montero, Miguel Á. Ortega, Miguel Ángel Alvarez‐Mon, et al.
Nutrients (2022) Vol. 14, Iss. 5, pp. 1107-1107
Open Access | Times Cited: 34
Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection
Miguel Á. Ortega, Oscar Fraile‐Martínez, Cielo García‐Montero, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 33
Characteristics of platelet-associated parameters and their predictive values in Chinese patients with affective disorders
YanYan Wei, Junhui Feng, Jinbao Ma, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 32
Management of depression in patients with coronary artery disease: A systematic review
Wọlé Akóṣílè, Babangida Tiyatiye, David Colquhoun, et al.
Asian Journal of Psychiatry (2023) Vol. 83, pp. 103534-103534
Open Access | Times Cited: 22
Identifying Neurophysiological Markers of Intermittent Theta Burst Stimulation in Treatment-Resistant Depression Using Transcranial Magnetic Stimulation–Electroencephalography
Rebecca Strafella, Davide Momi, Reza Zomorrodi, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 6, pp. 454-465
Closed Access | Times Cited: 21
Guidelines’ recommendations for the treatment-resistant depression: A systematic review of their quality
Franciele Cordeiro Gabriel, Aírton Tetelbom Stein, Daniela Oliveira de Melo, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281501-e0281501
Open Access | Times Cited: 18
The dynamic interaction between symptoms and pharmacological treatment in patients with major depressive disorder: the role of network intervention analysis
Claudia Savia Guerrera, Giuseppe Alessio Platania, Francesco Maria Boccaccio, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 18
The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression
Kaixin Wang, Shiqian Huang, Daan Fu, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 2
Open Access | Times Cited: 8
Repurposing General Anesthetic Drugs to Treat Depression: A New Frontier for Anesthesiologists in Neuropsychiatric Care
Connor T. A. Brenna, Benjamin I. Goldstein, Carlos A. Zarate, et al.
Anesthesiology (2024) Vol. 141, Iss. 2, pp. 222-237
Open Access | Times Cited: 8
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
Roger S. McIntyre, István Bitter, Jozefien Buyze, et al.
European Neuropsychopharmacology (2024) Vol. 85, pp. 58-65
Open Access | Times Cited: 8
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
Shruti M. Raja, Jeffrey T. Guptill, Michelle Mack, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 7
Economic impact of treatment-resistant depression: A retrospective observational study
Víctor Pérez, Miquel Roca, Jordi Alonso, et al.
Journal of Affective Disorders (2021) Vol. 295, pp. 578-586
Open Access | Times Cited: 39
Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
Alisha Sapkota, Hajra Khurshid, Israa A Qureshi, et al.
Cureus (2021)
Open Access | Times Cited: 36
Treatment-Resistant Depression in Poland—Epidemiology and Treatment
Piotr Gałecki, Jerzy Samochowiec, Magdalena Mikułowska, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 3, pp. 480-480
Open Access | Times Cited: 25
Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers
Ellen Scotton, Bárbara Antqueviezc, Mailton Vasconcelos, et al.
Biochemical Pharmacology (2022) Vol. 198, pp. 114963-114963
Closed Access | Times Cited: 25
Integrating Metabolomics and Network Analysis for Exploring the Mechanism Underlying the Antidepressant Activity of Paeoniflorin in Rats With CUMS-Induced Depression
Chaofang Lei, Zhigang Chen, Lili Fan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 25
Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression
Flurin Cathomas, Laura Bevilacqua, Aarthi Ramakrishnan, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Various neuromodulation methods including Deep Brain Stimulation of the medial forebrain bundle combined with psychopharmacotherapy of treatment-resistant depression—Case report
Joanna Rymaszewska, Tomasz Wieczorek, Karolina Fila-Witecka, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 16
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi, et al.
CNS Drugs (2023) Vol. 37, Iss. 8, pp. 715-723
Open Access | Times Cited: 16
Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis
Antonio Tundo, Sophia Betrò, Rocco de Filippis, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1043-1043
Open Access | Times Cited: 15

Scroll to top